Organization (Other)
Aga Khan Development Network
ClinicalTrials.gov lists Aga Khan Development Network as lead sponsor of 293 trials, counting the companies grouped under it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
16 sections measured, none recorded
This page covers Aga Khan Development Network and 1 company grouped under it: 293 lead-sponsored trials (0 its own, 293 in the grouped companies) and 5 legal-entity registrations (3 its own, 2 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Aga Khan University | 293 | 2 |
Disease areas (213)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Malnutrition | 29 |
| Hypertension | 19 |
| Anemia | 18 |
| Death | 17 |
| Growth Disorders | 15 |
Showing 5 of 213 disease areas.
Journals published in (427)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| BMJ open | 36 |
| Lancet (London, England) | 28 |
| The Cochrane database of systematic reviews | 28 |
| Reproductive health | 25 |
| The American journal of clinical nutrition | 21 |
Showing 5 of 427 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 21 | 15 | 2025-02-11 |
Financing and grant events (40)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-22 | NIH grant | 449,791 | Reporter |
| 2025-09-18 | NIH grant | 249,999 | Reporter |
| 2025-09-07 | NIH grant | 1,641,317 | Reporter |
| 2025-08-04 | NIH grant | 254,515 | Reporter |
| 2025-07-11 | NIH grant | 514,809 | Reporter |
Showing 5 of 40 events.
Organization relationships (98)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Gates Foundation | Co sponsors trial with | 11 |
| International Centre for Diarrhoeal Disease Research, Bangladesh | Co sponsors trial with | 5 |
| The Hospital for Sick Children | Co sponsors trial with | 4 |
| Government of the United States of America | Co sponsors trial with | 4 |
| Pakistan Ministry of Health | Co sponsors trial with | 4 |
Showing 5 of 98 relationships.
Latest dated events (442)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 442 events.
Biomarkers this organization publishes on (278)
Shown in this order: most publications first.
Showing 5 of 278 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, trials by start year as sponsor or collaborator, active development programs, approved assets, sponsor delivery record, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarker capability evidence.